Mom Fights to Get Life-Saving Fecal Transplant for Son

Blanca Morales watched her youngest son deteriorate for four months, learning to identify his Clostridioides difficile infection by smell alone. What started as routine strep throat in first grade spiraled into a nightmare when antibiotics wiped out the healthy bacteria in seven-year-old Mundo's gut, letting toxic C. diff take over.

By July, Mundo had endured three rounds of different antibiotics. Each time, his bloody diarrhea would vanish, only to return days after stopping treatment.

Morales wanted to try a fecal microbiota transplant, a procedure that seeds a sick person's gut with healthy bacteria from a donor's stool. It sounds unusual, but doctors have used it for decades to cure stubborn C. diff infections by restoring the diverse bacterial ecosystem that keeps dangerous microbes in check.

There was just one problem. At the end of 2024, the FDA halted shipments from OpenBiome, the national stool bank that had been supplying hospitals with screened fecal material since 2013. If Mundo had gotten sick a year earlier in Las Vegas, he could have received treatment within miles of his house.

The shutdown happened because two pharmaceutical companies got FDA approval for fecal-based drugs in 2022 and 2023. Federal officials said it closed a dangerous loophole, no longer allowing semi-regulated material when regulated alternatives existed.

But those approved drugs weren't tested on kids, the immunocompromised, or patients with severe C. diff. They also cost a fortune: one option lists at $19,680 for 12 pills, another at $9,411 for one enema bag. Insurance companies often refused to cover them, especially for off-label use in children like Mundo.

The Ripple Effect

Doctors across the country are now scrambling to help patients like Mundo access a treatment with a decades-long track record. Some hospitals are setting up their own donor programs, while researchers work to expand clinical trials that might give desperate families another path forward.

The irony stings: an FDA approval designed to make effective treatments more accessible instead created barriers for the most vulnerable patients. Meanwhile, families like the Morales are learning that in American healthcare, protecting patients on paper doesn't always translate to healing them in practice.

Morales put it simply: "It shouldn't be this hard to cure a child." Her persistence is now helping shine light on a gap in the system that affects thousands of families facing recurrent C. diff infections every year.